Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2018
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2018
SUMMARY
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 6 molecules. The latest report Histamine H4 Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.
The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Report covers products from therapy areas Dermatology, Ear Nose Throat Disorders, Immunology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Allergies, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis, Plaque Psoriasis (Psoriasis Vulgaris), Vertigo and Vestibular Neuronitis.
Furthermore, this report also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 6 molecules. The latest report Histamine H4 Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family. H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.
The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Report covers products from therapy areas Dermatology, Ear Nose Throat Disorders, Immunology and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Sensorineural Hearing Loss, Allergies, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis, Plaque Psoriasis (Psoriasis Vulgaris), Vertigo and Vestibular Neuronitis.
Furthermore, this report also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
- The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
Bioprojet SCR
JW Pharmaceutical Corp
Novartis AG
Palau Pharma SA
Sensorion SA
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
azasetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-7881A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JWP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliforant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPL-389 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2018: Sensorion receives approval to start Phase ll trial of SENS-401
Jul 24, 2018: Sensorion initiates safety study of Seliforant versus meclizine in evoked vestibular imbalance
Jun 29, 2018: Sensorion Shows Protective Effect of SENS-401 in Hearing Loss Models
Jun 06, 2018: Sensorion Announces Oral Presentation at the 15th International Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018)
Jun 01, 2018: Sensorion to Present at the 2018 BIO International Convention
Jun 01, 2018: Sensorion to Present SENS-401 at the 2018 BIO International Convention
May 02, 2018: World Health Organization Grants Name 'Seliforant' to Sensorion's SENS-111 Treatment
May 02, 2018: World Health Organization Grants Name ‘Seliforant’ to Sensorion’s SENS-111 Treatment
Apr 23, 2018: First Potential Biomarker for Noise-Induced Hearing Loss Identified
Apr 09, 2018: Sensorion to Present Data in Two Oral Sessions at the American Neurotology Society's 2018 Spring Meeting
Feb 14, 2018: Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting
Jan 24, 2018: Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting
Sep 12, 2017: Sensorion’s Oral Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study
Aug 22, 2017: Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients
Jun 08, 2017: Sensorion Takes a Key Step towards Phase 2 with SENS-401 Thanks to the Positive Results Obtained in the Phase 1 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
Bioprojet SCR
JW Pharmaceutical Corp
Novartis AG
Palau Pharma SA
Sensorion SA
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
azasetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-7881A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JWP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliforant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPL-389 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2018: Sensorion receives approval to start Phase ll trial of SENS-401
Jul 24, 2018: Sensorion initiates safety study of Seliforant versus meclizine in evoked vestibular imbalance
Jun 29, 2018: Sensorion Shows Protective Effect of SENS-401 in Hearing Loss Models
Jun 06, 2018: Sensorion Announces Oral Presentation at the 15th International Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018)
Jun 01, 2018: Sensorion to Present at the 2018 BIO International Convention
Jun 01, 2018: Sensorion to Present SENS-401 at the 2018 BIO International Convention
May 02, 2018: World Health Organization Grants Name 'Seliforant' to Sensorion's SENS-111 Treatment
May 02, 2018: World Health Organization Grants Name ‘Seliforant’ to Sensorion’s SENS-111 Treatment
Apr 23, 2018: First Potential Biomarker for Noise-Induced Hearing Loss Identified
Apr 09, 2018: Sensorion to Present Data in Two Oral Sessions at the American Neurotology Society's 2018 Spring Meeting
Feb 14, 2018: Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting
Jan 24, 2018: Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting
Sep 12, 2017: Sensorion’s Oral Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study
Aug 22, 2017: Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients
Jun 08, 2017: Sensorion Takes a Key Step towards Phase 2 with SENS-401 Thanks to the Positive Results Obtained in the Phase 1 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bioprojet SCR, H2 2018
Pipeline by JW Pharmaceutical Corp, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Palau Pharma SA, H2 2018
Pipeline by Sensorion SA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bioprojet SCR, H2 2018
Pipeline by JW Pharmaceutical Corp, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Palau Pharma SA, H2 2018
Pipeline by Sensorion SA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
Bioprojet SCR
JW Pharmaceutical Corp
Novartis AG
Palau Pharma SA
Sensorion SA
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
Bioprojet SCR
JW Pharmaceutical Corp
Novartis AG
Palau Pharma SA
Sensorion SA
